Connect Biopharma is trading 6.57% up at $0.96 on October 6; the immediate driver remains unclear.
- Its latest announced catalyst was positive preliminary Phase 2 COPD data released September 30, showing an 81% reduction in treatment failures versus placebo through Week 4.
- Earlier reporting tied a prior surge to those results, but they are not established as the cause of this session’s gain.
- Broader markets are higher while biotech is down 2.50%; no current company-specific catalyst or trading-volume figure was confirmed.